This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
GLP-1 receptor agonists — the drug class behind Ozempic, Wegovy, and Mounjaro — are among the most actively studied compounds in clinical medicine. In 2026, hundreds of trials are testing new oral formulations, ultra-long-acting injectables, and novel GLP-1-based combinations for obesity, type 2 diabetes, heart failure, Alzheimer's disease, and addiction. This guide explains how these trials work and how to find one you may qualify for.
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) is a hormone naturally released by the gut after eating. It stimulates insulin release, suppresses glucagon, slows gastric emptying, and signals the brain to reduce appetite. GLP-1 receptor agonists mimic this hormone with a much longer half-life — from hours (native GLP-1) to weeks (long-acting injectables).
FDA-approved GLP-1 drugs currently on the market include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity). These drugs have demonstrated unprecedented weight loss outcomes in clinical trials — 15–22% body weight reduction — and significant cardiovascular and kidney benefits.
What's Being Tested in 2026
Oral GLP-1 formulations are the most anticipated development in the field. Rybelsus (oral semaglutide) already exists but requires fasting and strict timing. New compounds like orforglipron (Eli Lilly) and danuglipron (Pfizer) are small-molecule GLP-1 agonists that can be taken without food restrictions. Phase 3 trials for orforglipron reported ~16% weight loss — comparable to injectable semaglutide — with a convenient once-daily tablet.
Triple agonists such as retatrutide (GLP-1/GIP/glucagon) are showing weight loss of over 24% in Phase 2 trials — the highest ever recorded for a pharmaceutical intervention. Phase 3 trials are ongoing as of 2026.
Ultra-long-acting injectables designed for once-monthly or once-quarterly dosing are in early trials. Pfizer's lotiglipron and several undisclosed compounds from Novo Nordisk and AstraZeneca aim to extend dosing intervals to reduce burden on patients.
GLP-1 for Alzheimer's disease is a rapidly growing area. GLP-1 receptors are expressed in the brain, and epidemiological data suggests GLP-1 users have lower rates of dementia. The EVOKE and EVOKE+ trials (semaglutide vs. placebo in early Alzheimer's) reported results in late 2025 and are generating significant follow-up research.
GLP-1 for heart failure, kidney disease, sleep apnea, MASH (metabolic-associated steatohepatitis), and substance use disorders are all being studied in active Phase 2 and Phase 3 trials.
Who Qualifies for GLP-1 Trials?
Eligibility varies by trial, but common inclusion criteria include:
- Obesity trials: BMI ≥ 30 kg/m², or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea)
- Diabetes trials: Type 2 diabetes diagnosis, HbA1c typically 7.5–11%, on stable background therapy
- Cardiovascular trials: Established cardiovascular disease or high CV risk
- Alzheimer's trials: Early-stage cognitive impairment, specific amyloid or tau biomarker levels
Common exclusion criteria include: personal or family history of medullary thyroid carcinoma or MEN2, severe gastrointestinal disease, pregnancy, recent major cardiovascular event (varies by trial), or prior GLP-1 use (for some trials).
What to Expect as a Participant
GLP-1 trials typically last 52–72 weeks for Phase 3 obesity and diabetes trials. Participants receive either the investigational drug or an active comparator (sometimes placebo, though placebo-only arms are less common now given the established efficacy of the class). Visits occur every 4–12 weeks and include weight measurements, blood work, and safety assessments.
Side effects most commonly reported in GLP-1 trials are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually most pronounced in the first 8–12 weeks during the dose-escalation period and diminish with time. Serious adverse events are rare but include pancreatitis and gallbladder disease.
How to Find a GLP-1 Trial
The most complete database of active GLP-1 trials is ClinicalTrials.gov, maintained by the NIH. You can search by condition ("obesity," "type 2 diabetes") and filter by status (Recruiting), proximity, and age. ClinicalMetric indexes all currently recruiting trials and updates daily from ClinicalTrials.gov, making it easy to find studies by condition or drug name.
Your physician can also refer you to trials at academic medical centers, which often run industry-sponsored GLP-1 studies. Patient advocacy organizations for diabetes (ADA, JDRF) and obesity (OAC) maintain trial finder tools as well.
Key Questions to Ask Before Enrolling
- Is this a placebo-controlled trial, or will I definitely receive active medication?
- What happens to my treatment after the trial ends?
- How many visits are required, and what is the travel reimbursement policy?
- Are there weight loss support resources (dietitian, exercise guidance) included?
- What is the dose escalation schedule and how are GI side effects managed?